Press coverage about Diplomat Pharmacy (NYSE:DPLO) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.1386461566674 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
Several research analysts recently issued reports on the company. Deutsche Bank downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $22.00 to $29.00 in a research report on Friday, February 2nd. Credit Suisse Group upgraded Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price objective for the company in a research report on Thursday, January 25th. Mizuho set a $25.00 price objective on Diplomat Pharmacy and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Zacks Investment Research downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, Lake Street Capital assumed coverage on Diplomat Pharmacy in a research report on Friday, February 9th. They set a “buy” rating and a $35.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Diplomat Pharmacy currently has an average rating of “Hold” and an average price target of $25.38.
DPLO stock traded down $0.04 during midday trading on Thursday, hitting $19.80. The stock had a trading volume of 508,243 shares, compared to its average volume of 925,982. Diplomat Pharmacy has a 12-month low of $14.23 and a 12-month high of $27.78. The stock has a market capitalization of $1,450.28, a P/E ratio of 23.57 and a beta of 1.32. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 0.97.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the company earned $0.08 EPS. The business’s quarterly revenue was up .9% compared to the same quarter last year. research analysts forecast that Diplomat Pharmacy will post 0.94 earnings per share for the current fiscal year.
In other news, Director Philip R. Hagerman sold 2,150,000 shares of the business’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $20.65, for a total transaction of $44,397,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 30.20% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Diplomat Pharmacy (NYSE:DPLO) Receiving Somewhat Positive Media Coverage, Accern Reports” was originally published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://macondaily.com/2018/04/12/diplomat-pharmacy-dplo-earns-daily-media-impact-score-of-0-17-updated-updated-updated.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.